Please ensure Javascript is enabled for purposes of website accessibility

Is Moderna Stock Overvalued -- or a Bargain?

By Adria Cimino - Updated Jun 23, 2021 at 8:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Let's take a look at revenue prospects.

Moderna (MRNA -1.41%) shares have soared over the past year. Investors bet on the company's ability to bring a vaccine to market -- and then make billions of dollars in revenue. In this Motley Fool Live video recorded on May 28, 2021, Healthcare and Cannabis Bureau Editor and Analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss Moderna's valuation and whether there is still room for the biotech stock to gain over the long term.

Olivia Zitkus: My last Moderna specific question for you, just to know where it's trading right now, do you think it's run up a lot over the past year? Do you think it's looking a little too expensive or maybe cheap given its potential? I've seen lots of people on both sides of that spectrum, so what's your thinking there?

Adria Cimino: I'm on the side where I say it's looking kind of like a bargain. The stock is up 180% over the past year, which seems like a whole lot, and it is. But we have to remember that it's trading at about seven times forward earnings estimates, and when we look at the vaccine and the possibility of the booster and the possibility that it's going to be expanded perhaps to kids and teens. Then we look at the pipeline, the cytomegalovirus vaccine candidate is about to enter a phase 3 pivotal trial later on this year, so that's a late-stage program. There are other things on the horizon. We look at all that for the idea of long-term investing, there is a lot down the road from Moderna, so I would say that right now still represents a good opportunity to get in on the stock.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus owns shares of Moderna Inc. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$171.81 (-1.41%) $-2.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.